

G		Investigational product GMP	86
GCP		Investigational products	
General requirements	85	Quality	81
General Affairs Division	2	Issues Related to the Use of Determination of	
GMP		Unapproved Drugs and Off-label Use	172
Compliance review	68	J	
Global harmonization	68	JAPAN AGENCY FOR MEDICAL RESEARCH AND	
GMP compliance inspection	67	DEVELOPMENT (AMED)	9
Good Clinical Practice (GCP)	26	Japanese Pharmacopoeia (JP)	45
Good Laboratory Practice (GLP)	26, 77	K	
Good Manufacturing Practice (GMP)	22	Kansai Branch	9
Good Post-marketing Study Practice (GPSP)	28	L	
Good Vigilance Practice (GVP)	119	Labeling and Package Inserts	24
Government Batch Test		Labeling of excipients	150
Quality Of Drugs	48	Law Concerning Access to Information	30
GPSP		License for Manufacturing Business and Accreditation of	
Compliance status for reexamination	130	Overseas Manufacturers	20
GPSP	28, 126	License for Manufacturing/Marketing Businesses	19
Guidance-mandatory drugs	17	M	
Guidelines		Manufacturing/Marketing Approval Application	35
Clinical evaluation	85	Manufacturing/Marketing Approvals	
Guidelines Concerning Drug Approval Applications	74	Marketing Approval Reviews	33
Guidelines for bioequivalence Studies	79	Marketing Approvals	33
Guidelines for Other Pharmacological Studies	78	Medical benefits under NHI programs	167
Guidelines for Pharmacokinetic Studies	79	Medical Devices Evaluation Division	2
Guidelines for Stability Tests	76	Drug Master File (MF)	23
Guidelines for Toxicity Tests	76	Microdose studies	83
Guidelines on Physicochemical Properties, Specifications,		Ministry of Health, Labour and Welfare (MHLW)	
and Tests Methods	75	Organization and function	1
GVP	119	N	
H		National Institute of Biomedical Innovation, health and	
Health and Medical Services Law for the Aged	166	nutrition (NIBIOHN)	9
Health insurance programs	166	National Institute of Health Sciences (Health Sciences) ..	5
Health Policy Bureau (HPB)	4	National Institute of Infectious Diseases (NIID)	10
History of health insurance programs	166	NHI price list	168
Hokuriku Branch	9	NHI reimbursement of medical fees	167
I		Nonclinical studies	
ICH	91	Requirements	80
Infectious Diseases Information Center	10	Non-prescription drugs	17
Information for drugs which completed reexamination or		Non-prescription Drugs	73
reevaluation	158		
International Conference on Harmonization (ICH)	91		
Interview advice meetings	61		

O

Office of Advanced Evaluation with Electronic Data	9
Office of Cellular and Tissue-based Products	7
Office of Chemical Safety	3
Office of Drug Induced Damages	2
Office of Generic Drugs	7
Office of In Vitro Diagnostics	8
Office of Informatics and Management for Safety	8
Office of International Cooperation	8
Office of International Programs	8
Office of Manufacturing Quality and Vigilance for Medical Devices	8
Office of Manufacturing Quality for Drugs	8
Office of Medical Devices I	7
Office of Medical Devices II	7
Office of Medical Informatics and Epidemiology	9
Office of New Drug I	6
Office of New Drug II	6
Office of New Drug III	6
Office of New Drug IV	7
Office of New Drug V	7
Office of Non-clinical and Clinical Compliance	7
Office of OTC/Quasi-drugs	7
Office of Pharmacovigilance I	8
Office of Pharmacovigilance II	8
Office of Review Administration	6
Office of Review Management	6
Office of Standards and Compliance for Medical Devices	8
Office of Vaccines and Blood Products	7
On-site reviews	67
Orphan Drugs	37
Outline of pharmaceutical regulations	17
Outline of prescription of drug information	153

P

Package inserts	
Background	145
Headings and their sequence	148
Information to supplement package Inserts	152
Non-prescription drugs	160
Style and format	147
PACKAGE INSERTS OF GUIDANCE-MANDATORY DRUGS	160
Packaging Strategy for World-first Products	39
Paper reviews	67
Patent System	31

Patient-requested Therapy System	28
Periodic safety reports	136
Pharmaceutical Affairs and Food Sanitation Council (PAFSC)	9
Pharmaceutical and Medical device act	15
Pharmaceutical Interview Forms (IF)	153
Pharmaceutical laws	15
Pharmaceutical laws and regulations	15
Pharmaceutical Safety and Environmental Health Bureau (PSEHB)	2
Pharmaceutical Safety Division	3
Pharmaceutical Supervision	48
Pharmaceuticals and Medical Devices Agency (PMDA, KIKO)	5
Pharmacological studies	
Requirements	81
Phase I of clinical studies	82
Phase II of clinical studies	82
Phase III of clinical studies	82
Phase IV of clinical studies	83
Phases of clinical development	81
PMS	116
Post-marketing surveillance (PMS)	116
Precautions (package inserts)	149
Prescription drugs	17
Prescription Drugs	73
Prevention of Medical Accidents	49
Pricing formula for reimbursement price revisions	168
Priority Review System	36
Priority reviews	15
Procedures for Clinical Trials	58
Product Recalls	48
Proper Advertisement	25
Public disclosure of information on new drug development	90

Q

Quality and Nonclinical Studies	75
---------------------------------	----

R

Recent revisions of NHI price list	170
Reevaluation	29
Reevaluation	
System	138
Reexamination	28
Data and procedures	137

Pharmaceutical Regulations in Japan:

Designated classifications.....	138	Specified biological products.....	18
Designation of drugs	136	Safety Measures against Bovine.....	49
System	135	Standards for Biological Materials.....	47
Regulations for Imported Drug Management and Quality		Structure and Layout of Package Insert for Prescription	
Control	69	Drugs	162
Reimbursement prices for new drugs.....	171	Studies of drug interactions.....	83
Reporting of Adverse Drug Reactions from Patients	134	Studies of drug metabolites.....	83
Research and Development Division	4		
Restrictive Approval System.....	37	T	
Risk management plan (RMP)	123	Trial Conducted from a Compassionate Viewpoint	
Risk Management Plan (RMP).....	29	(expanded trial).....	27
S		U	
Safety flash report	156	Unapproved drugs and drugs of off-label use	38
Safety information			
Reporting system by Medical Personnel.....	133	W	
Safety monitoring		WHO safety monitoring program.....	134
During clinical studies	60	Y	
Safety studies		Yellow letter	155
Requirements.....	81		
SOP for PMS.....	121		

Participating Company List

Under the supervision of Ministry of Health Labour and Welfare Japan, this publication has been updated regularly with the cooperation of the enthusiastic editors below.

Leader: Katsunori KURUSU

(Chapter 1)	Sanofi KK	R&D Regulatory Regulatory Affairs: Katsunori KURUSU
(Chapter 2)	EA Pharma Co, Ltd	Regulatory Affairs: Michiyuki SUZUKI
	Takeda Pharmaceutical Company Limited	Regulatory Affairs: Akira YATSUSHIGE
(Chapter 3)	Daiichi Sankyo Co, Ltd	New Drug Regulatory Affairs: Yuko ARAMAKI
	Janssen Pharmaceutical KK	Regulatory Operation & Intelligence: Taihei SHIRASAKA
	MSD KK	Regulatory Policy & Intelligence: Kanji HIRAI, Jun ONO
	UCB Japan Co, Ltd	Regulatory Affairs: Yasuhiro HASEGAWA
(Chapter 4)	Mitsubishi Tanabe Pharma Corporation	Global Regulatory Affairs: Mamoru IKEDA
	Shionogi & Co, Ltd	Regulatory Affairs: Kazuyo MARUCHI
(Chapter 4)	Kyowa Kirin Co, Ltd	PV Operations: Hiroyuki OHTSUKA
(Chapter 5)	Chugai Pharmaceutical Co, Ltd	Regulatory Intelligence & Management: Yasuhiro KITSUTA
(Chapter 6)	Otsuka Pharmaceutical Co, Ltd	Regulatory Affairs: Toshio SATO
		Medical Regulatory Affairs: Hirohisa TODO

Contact:

Administrative Office	JAPAN PHARMACEUTICAL MANUFACTURERS ASSOCIATION	Office of International Affairs
	2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-0023, Japan e-Mail address: international @ jpma.or.jp Phone 81-3 (3241) 0326 Fax 81-3 (3242) 1767	